Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect.

Bausch + Lomb beat analysts’ revenue expectations last quarter, reporting revenues of $1.39 billion, up 9.1% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance meeting analysts’ expectations but EPS in line with analysts’ estimates.

Is Bausch + Lomb a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Bausch + Lomb’s revenue to grow 7.1% year on year, in line with the 7.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Bausch + Lomb rarely misses Wall Street’s revenue estimates.

Looking at Bausch + Lomb’s peers in the healthcare equipment and supplies segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 21.7%, beating analysts’ expectations by 5.3%, and Neogen reported revenues up 6.5%, topping estimates by 7%. Intuitive Surgical traded down 2.3% following the results while Neogen was also down 2.3%.

Read our full analysis of Intuitive Surgical’s results here and Neogen’s results here.

There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 3.1% on average over the last month. Bausch + Lomb is up 3.7% during the same time and is heading into earnings with an average analyst price target of $19.39 (compared to the current share price of $17.57).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.